Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US contemplates changes to prevent another tainted heparin-like event

This article was originally published in SRA

Executive Summary

At a time when Republicans are seeking to cut more than $240 million from the US Food and Drug Administration's budget, the agency is facing an enormous challenge keeping up with inspections of foreign facilities where US drugs are made – with the number of those sites increasing 185% over the past decade – while also combating the rising problem of counterfeit medicines reaching the US supply chain.

Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS116021

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel